NewEdge Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
NewEdge Advisors's NBIX Position: Q3 2026 in Review
NewEdge Advisors increased its Neurocrine Biosciences (NBIX) stake by 1.1% in Q3 2026, buying an estimated $22.5K and bringing the position to 12,759 shares worth $1.81M. The position accounts for 0.01% of the portfolio, ranked #1283.
NewEdge Advisors first reported a position in NBIX in Q4 2022 and has held it in 16 quarters since. The position peaked at $2.13M in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- NewEdge Advisors held 12,759 shares of Neurocrine Biosciences worth $1.81M as of Q3 2026.
- NewEdge Advisors bought 140 Neurocrine Biosciences shares in Q3 2026, an estimated $22.5K.
- Neurocrine Biosciences made up 0.01% of NewEdge Advisors's portfolio in Q3 2026, its #1283 holding.
- NewEdge Advisors first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 16 quarters since.
- NewEdge Advisors's Neurocrine Biosciences position peaked at $2.13M in Q2 2026.
- 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.